CA2987324C - Cerdulatinib for the treatment of b-cell malignancies - Google Patents

Cerdulatinib for the treatment of b-cell malignancies Download PDF

Info

Publication number
CA2987324C
CA2987324C CA2987324A CA2987324A CA2987324C CA 2987324 C CA2987324 C CA 2987324C CA 2987324 A CA2987324 A CA 2987324A CA 2987324 A CA2987324 A CA 2987324A CA 2987324 C CA2987324 C CA 2987324C
Authority
CA
Canada
Prior art keywords
cerdulatinib
mutation
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2987324A
Other languages
English (en)
French (fr)
Other versions
CA2987324A1 (en
Inventor
Anjali Pandey
Gregory COFFEY
Janet Leeds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CA2987324A1 publication Critical patent/CA2987324A1/en
Application granted granted Critical
Publication of CA2987324C publication Critical patent/CA2987324C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2987324A 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies Active CA2987324C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168530P 2015-05-29 2015-05-29
US62/168,530 2015-05-29
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
PCT/US2016/034861 WO2016196385A1 (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Publications (2)

Publication Number Publication Date
CA2987324A1 CA2987324A1 (en) 2016-12-08
CA2987324C true CA2987324C (en) 2023-08-22

Family

ID=57441822

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2987324A Active CA2987324C (en) 2015-05-29 2016-05-27 Cerdulatinib for the treatment of b-cell malignancies

Country Status (9)

Country Link
US (2) US20180147203A1 (https=)
EP (1) EP3302485B1 (https=)
JP (2) JP7258462B2 (https=)
KR (1) KR102613106B1 (https=)
CN (1) CN107683139A (https=)
AU (1) AU2016270658B2 (https=)
CA (1) CA2987324C (https=)
ES (1) ES2958412T3 (https=)
WO (1) WO2016196385A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
AU2016363005A1 (en) 2015-12-04 2018-07-05 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
US20180065317A1 (en) 2016-09-06 2018-03-08 Cc3D Llc Additive manufacturing system having in-situ fiber splicing
WO2018189566A1 (en) * 2017-04-10 2018-10-18 Dorian Bevec Use of a chemical compound as a therapeutic agent
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib
EP3787628A1 (en) * 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Methods for treating lymphoma
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
US20230181581A1 (en) * 2020-05-26 2023-06-15 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
MX2009000769A (es) 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
AR076550A1 (es) 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
EP2741747A1 (en) * 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
JP2015522091A (ja) 2012-06-27 2015-08-03 ノボマー， インコーポレイテッド ポリエステル生成のための触媒および方法
CN104704129A (zh) * 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
CN105282602A (zh) 2014-07-07 2016-01-27 乐视致新电子科技（天津）有限公司 数据处理方法、装置及移动终端设备
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
AU2016363005A1 (en) * 2015-12-04 2018-07-05 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers

Also Published As

Publication number Publication date
ES2958412T3 (es) 2024-02-08
EP3302485B1 (en) 2023-07-12
US12350269B2 (en) 2025-07-08
JP2021152076A (ja) 2021-09-30
EP3302485A1 (en) 2018-04-11
JP2018520117A (ja) 2018-07-26
KR102613106B1 (ko) 2023-12-12
AU2016270658B2 (en) 2021-08-12
US20220096471A1 (en) 2022-03-31
WO2016196385A1 (en) 2016-12-08
AU2016270658A1 (en) 2018-01-04
JP7258462B2 (ja) 2023-04-17
CA2987324A1 (en) 2016-12-08
KR20180011210A (ko) 2018-01-31
CN107683139A (zh) 2018-02-09
US20180147203A1 (en) 2018-05-31
EP3302485A4 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
CA2987324C (en) Cerdulatinib for the treatment of b-cell malignancies
US11446300B2 (en) Cerdulatinib for treating hematological cancers
EP3328375B1 (en) Methods for cancer and immunotherapy using glutamine analogues, including don
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
CN102427814A (zh) 激酶蛋白结合抑制剂
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
JP2019512003A (ja) コパンリシブバイオマーカー
JP2019511204A (ja) コパンリシブバイオマーカー
CN108392634A (zh) B7s1抑制剂在制备肝癌药物中的用途
EP3810200B1 (en) Compositions for treating melanoma
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
JP7399883B2 (ja) 併用療法のための患者の選択
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK40000537A (en) Copanlisib biomarkers
HK40001092A (en) Copanlisib biomarkers
Ucar Targeting protein interactions of FAK and IGF-1R in human cancer as a novel anti-neoplastic approach

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210428

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425